Latest News
MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022
Alderley Park, Cheshire, U.K – Infex Therapeutics, a leader in critical-priority infectious diseases, is pleased to announce it has received approval from the...
Maxwellia has appointed Ian Adamson as strategic advisor to shape the next phase of pharmacy medicine launches – a process which involves identifying and converting suitable prescription only medicines into versions people can choose to...
2 April 2022 - Manchester, UK. The GM&C Life Sciences Fund, managed by Catapult Ventures, has announced a 3.3x cash return (115.6% IRR), from its exit of Panthera Biopartners Ltd.
The exit comes as part of a £10m further funding p...
MANCHESTER, England, April 22, 2022 /PRNewswire/ -- Following the reclassification of the daily progestogen-only pill earlier this year, Maxwellia made history by launching Lovima® (desogestrel 75mcg) one of the first oral...
Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology Target
OXFORD, England and SAN JOSE, Calif., April 13, 2022 /...